

Cite this: *RSC Chem. Biol.*, 2025, 6, 666

Peptides: potential delivery systems for mRNA

Huiting Liang,^a Yun Xing,^b Kexin Wang,^c Yaping Zhang,^{*a} Feng Yin^{ib} ^{*ab} and Zigang Li^{ib} ^{*ab}

mRNA-based therapies have broad applications in various disease treatments and have been applied in protein replacement therapy, gene editing, and vaccine development. Numerous research studies have been carried out aiming to increase the stability of mRNA, improve its translational efficiency, and reduce its immunogenicity. However, given mRNA's large molecular size and strong electronegativity, the safety and efficient delivery of mRNA into the target cells remains the critical rate-limiting step in current mRNA drug development. Various nanocarriers, such as liposomes, lipid nanoparticles, polyetherimide, and mesoporous silica nanoparticles, have been employed for mRNA delivery in the past few decades. Among them, peptides have demonstrated great potential as promising carrier candidates for mRNA delivery due to their high cell membrane permeability, good biocompatibility, definite chemical structure, and ease of preparation. Here, peptide-based mRNA delivery systems are systematically analyzed, including their construction strategies, mechanisms of action in mRNA delivery, and the application limitations or challenges. It is hoped that this review will guide the design, optimization, and applications of peptide carriers in mRNA-based drug development.

Received 2nd December 2024,
Accepted 17th February 2025

DOI: 10.1039/d4cb00295d

rsc.li/rsc-chembio

1 Introduction

In the last few decades, ribonucleic acid (RNA)-based therapy has emerged as a promising approach for treating various diseases. Recently, multiple RNA drugs have been developed and applied in several fields, including gene inhibition, gene insertion, gene editing, and protein expression. By the end of 2023, 18 nucleic acid drugs (excluding 3 delisted products) had been approved by the U.S. Food and Drug Administration (FDA), including 9 antisense oligonucleotides (ASOs), 6 small interfering RNAs (siRNAs), 1 aptamer, and 2 messenger ribonucleic acids (mRNAs).^{1,2} Unlike oligonucleotides (siRNA/ASO/aptamer), mRNAs with longer sequences have unique therapeutic applications due to their ability to produce any peptide/protein in transfected cells transiently. Therefore, mRNA drugs have broad application prospects in protein replacement, gene editing, and vaccine development. mRNA drugs are classified into two main categories: mRNA therapeutic drugs and mRNA vaccines.³ The drugs that utilize the translation function of mRNA molecules to intervene in disease processes are referred to as mRNA therapeutic drugs. Compared with traditional

small molecule drugs or recombinant proteins, mRNA drugs have advantages such as relatively simple development and production.⁴ In comparison to DNA medicines, mRNA drugs have the characteristics of rapid expression and no risk of genomic integration.⁵ Furthermore, mRNA vaccines encoding antigens can elicit more robust cellular and humoral immune responses than traditional vaccines.⁶ This results in a higher protection rate. The outbreak of the novel coronavirus SARS-CoV-2 (COVID-19) in 2019 has accelerated the success of mRNA drug development and clinical approval. In 2020, Pfizer developed the first mRNA vaccine based on lipid nanoparticle (LNP) carriers and it was approved for the prevention of SARS-CoV-2 infection.⁷ This was a major turning point for the development of mRNA therapies. Since then, several nucleic acid drug research and development companies, represented by Moderna and BioNTech, have joined the competition for mRNA drug development, and have continued to expand the potential of mRNA in various scenarios, such as tumor immunotherapies,⁸ autoimmune diseases,⁹ and rare genetic diseases.¹⁰

However, compared to oligonucleotide drugs, mRNA has a larger molecular weight and size, as well as a stronger electronegativity, which makes it more difficult for mRNA to enter cells and exert effects. As a result, the development of safe and efficient mRNA delivery carriers has remained a challenging and crucial step in the progression of mRNA drugs. In the past few decades, researchers have focused on optimizing delivery vectors to protect mRNAs from degradation and promote their cytoplasmic delivery. Commonly, a qualified mRNA delivery

^a Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen 518118, China. E-mail: yapi_zhang@163.com

^b State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China. E-mail: yinfeng@pkusz.edu.cn, lizg@pkusz.edu.cn

^c Department of Chemistry, Southern University of Science and Technology, Shenzhen, 518055, China



carrier should meet the following requirements:¹¹ (i) the carrier needs to be capable of effectively compressing micrometer-sized mRNA into a nanometer-sized complex, which further avoids nuclease-mediated nucleic acid drug degradation and enhances the cellular uptake of mRNA; (ii) the complex can selectively accumulate in the desired tissues and cells, and assist mRNA efficient internalization by the target cells; (iii) the carrier is capable of intracellular escape from the endosomal cytosol, allowing for effective nucleic acid drug delivery to the cytoplasm to exert their effects; (iv) the carrier is safe and stable with low immunogenicity; and (v) the circulation time of mRNA *in vivo* could be effectively extended by introducing carriers into the system.

To satisfy these requirements, among different types of delivery systems, viral vectors have attracted attention in mRNA delivery due to their high transfection efficiency. At present, numerous viral delivery carriers have been developed, including lentiviral vectors, adenovirus, and adeno-associated virus vectors.¹² However, the safe application of virus-based carriers remains a challenge due to the high inherent immunogenicity of viruses and the potential risk of gene insertion. In recent years, a variety of non-viral carriers have been developed as alternatives to viral carriers, which have gradually gained popularity for mRNA delivery, such as lipid-based delivery systems, inorganic nanoparticles, polycationic polymers, extracellular vesicles, hydrogels, peptides, and nucleic acid nanoassemblies.^{13–17} These novel non-viral carriers not only demonstrate commendable performances in improving mRNA stability and delivery efficiency, but also make important improvements in critical criteria including biocompatibility, toxicity, immunogenicity, and targeting. Mesoporous silica nanoparticles, as a representative of inorganic nanocarriers, can achieve high mRNA loading due to their mesoporous structure and large specific surface area. Their easily modifiable surface also provides the possibility for further improvement in the stability and targeting of mRNA drugs.¹⁸ Polyethyleneimine (PEI), as a representative of polycationic polymers, has demonstrated the ability to induce efficient nucleic acid aggregation. Biocompatible molecules such as cyclodextrin and polyethylene glycol (PEG) have been introduced into the carrier to reduce the charge density of PEI, and to improve the safety of PEI carriers while maintaining their nucleic acid delivery performance.^{19–21} In addition, to improve the biocompatibility of the carrier and reduce its immunogenicity, extracellular vesicles, represented by exosomes, are also developed for mRNA delivery. They have presented good specificity in the targeted delivery of mRNA to the desired tissues and organs.²² Furthermore, nucleic acid nanoassemblies, formed through rolling circle transcription,²³ smart-responsive DNA nanogels,²⁴ and mRNA nanoassembly strategies²⁵ have made significant progress in extending mRNA half-life, enhancing protein expression levels, and optimizing intracellular release. As representatives of lipid-based delivery systems, LNPs were the first delivery system approved by the FDA for the novel coronavirus (SARS-CoV-2) mRNA vaccine,⁷ due to their mRNA protection, improved delivery efficiency, biosafety, and industrialization advantages.

LNP delivery technology is currently the first choice for nucleic acid drug delivery.²⁶ Despite the many advantages of

LNP delivery systems, unmodified LNP drug delivery systems have significant limitations, such as potential cytotoxicity, lack of targeting selectivity, short circulation time, poor endosomal escape, and the need for extreme storage conditions (such as freezing). Improved LNP formulations aim to overcome these drawbacks.^{27–32} Peptides derived from biological sources are expected to circumvent the aforementioned limitations of LNP application and can be excellent mRNA delivery systems. First, peptides, derived from natural products, were widely explored for exhibiting good biocompatibility and biodegradability.^{33,34} Also, peptides demonstrate remarkable cell-penetrating efficiency, precise targeting specificity, and a versatile array of chemical modification sites,^{15,35–37} all of which synergistically enhance the targeting efficacy of peptide-based nucleic acid delivery platforms. Furthermore, it was shown that peptide carriers and nucleic acids can be formulated into dry powder preparation *via* spray drying without compromising their physical integrity and biological activity.^{38,39} This suggests that peptide-based carriers may address the storage limitations associated with LNPs. In summary, peptide-based carriers hold significant promise for overcoming the limitations of LNPs, particularly in terms of biosafety, targeting specificity, and storage requirements.

A few studies have reviewed the application of peptide carriers in small nucleic acid drugs. However, in this article, we mainly focus on the progress of research on peptide-based carriers in mRNA drug delivery. The construction strategy, mechanism of action, and application limitations of the peptide nano-carrier system are also analyzed in detail. It is hoped that this comprehensive overview will provide a reference for the redesign and optimization of the new generation peptide carriers.

2 Peptides as carriers for mRNA delivery

Multifunctional peptides obtained by the arrangement of different amino acids offer the possibility to facilitate efficient cell penetration or deliver nucleic acid drugs to specific organs or organelles.⁴⁰ Protamine, cell-penetrating peptides (CPPs), and cell membrane protein-targeting peptides have been proven to be effective for mRNA delivery. According to the contribution rate of peptides in the delivery carrier, peptide-based carriers can be divided into two categories: (i) mRNA delivery carriers based on single-component peptides that primarily rely on the peptides for facilitating mRNA delivery; (ii) peptides are combined with other carrier materials for mRNA delivery, primarily to overcome the limitations of the original carriers. Specifically, mRNA delivery dominated by peptides can be subdivided into cationic peptide-driven delivery, amphipathic peptide-driven delivery, mRNA-peptide covalent conjugate delivery, and phase separation-driven delivery. The recent categories of peptides used for efficient mRNA delivery are summarized in Table 1.

2.1 mRNA delivery carriers based on single-component peptides

2.1.1. Cationic peptide-driven mRNA delivery. Cationic peptides are some of the top choices for RNA delivery vehicles



Table 1 Examples of recent peptides for mRNA efficient delivery

Delivery system type	Name of the delivery system	Amino acid sequence	<i>In vivo</i> model	Ref.
Cationic peptides	Protamine	MPPRRRSSSRPVRRRRRPRVSRRRRRRGRRRR	Phase I	41
	H3K(+H)4b	A four branches peptide, KHHHKHHHKHHHKHHHK in each branch	n.d. ^b	42
Amphipathic cationic peptides	p5RHH	VLTTGLPALISWIRRRHRRHC	Mice	43
	RALA	WEARLARALARALARHLARALARALRACEA	Mice	44
	LAH4-L1	KKALLAHALHLLALLALHLAHALKKA	n.d.	45
	LAH4-L1R	RRALLAHALHLLALLALHLAHALRRA	n.d.	46
	HELP-4H	GLGTLTLLHFLHLLHLLHFLKRKRQQ	n.d.	47
Covalent binding	PepFect14	Stearyl- AGYLLGKLLLOOLAAAALOOOL ^a	Mice	48
	—	PFVYLI	n.d.	49
Phase-separated peptide	HB <i>pep</i> -SR	GHGVIY-GHGVIY-GHGVIY-K-GHGVIY-GHGLYV (K was modified by NHS-SS-R, R = Ac/Ph)	n.d.	50
Lipid/peptide hybrid delivery system	LNP modified by peptide KALA	KALA: WEAKLAKALAKALAKHLAKALAKALKA	Mice	51
Polymer/peptide hybrid delivery system	DOTAP liposomes, modified by DP7-C	DP7-C: cholesterol-modified VQWRIRVAVIRK	Mice	52
	PEG ₁₂ KL4	PEG ₁₂ -KLLLLKLLLLKLLLLKLLLLK	Mice	53
	PEG ₁₂ LAH4-L1	PEG ₁₂ -KKALLAHALHLLALLALHLAHALKKA	Mice	54
	PLA and LAH4-L1	LAH4-L1: KKALLAHALHLLALLALHLAHALKKA	n.d.	45

^a O: ornithine. ^b n.d. = not determined.

due to the strong negative charge of mRNA.⁵⁵ Positively charged cationic peptides assemble with the negatively-charged mRNA through electrostatic interactions to form nanometer-sized particles. Thanks to the cell's unique way of up-taking nanoparticles *via* endocytosis, the mRNA is efficiently delivered into the cell. On the one hand, the positively charged peptide carrier protects the mRNA from degradation by nucleases.⁵⁶ On the other hand, it can further enhance the drug delivery efficiency by increasing the adhesion of the nanoparticles to the negatively charged cell membrane.⁵⁷ Protamine, consisting of 30–50 amino acids, is the first type of cationic arginine-rich peptide used in mRNA delivery research^{58,59} (note: compounds made up of 10–50 amino acids linked by peptide bonds are defined as peptides, so protamine is classified as a peptide here⁶⁰). Due to its natural origin and good biosafety, protamine has become the first non-liposome mRNA delivery system to enter clinical trials (Fig. 1a). Recently, mRNA drugs based on protamine have been used to treat metastatic melanoma cancer (NCT00204607), prostate cancer (EudraCT 2008-003967-37, NCT0187738), non-small cell lung cancer (NCT00923312, NCT01915524) and many other malignant tumors.⁵⁹ Besides, a prophylactic vaccine against the rabies virus developed by CureVac AG has entered phase I clinical trials (NCT02241135).⁴¹

However, the presence of high-density positive charges impedes the release of nucleic acids from the complex, which in turn affects the transfection activity of protamine.⁶¹ Therefore, to further improve the carrier's transfection efficiency, researchers have focused on the development of synthetic cationic peptide carriers with shorter sequences, which are easier to synthesize with better stability and delivery efficiency. In the early stages, short-chain peptide carriers are effective in the delivery of oligonucleotide drugs such as siRNA.⁶² Consequently, pioneering researchers attempted to directly utilize the commonly used R8, TAT, and other cationic cell-penetrating peptides for the delivery of mRNA. Kim's group evaluated and compared the delivery effects of short-chain cationic peptides such as R8, TAT, and low molecular weight protamine (LMWP)

on mRNA, including encapsulation, cellular uptake, and protein expression.⁶³ Unfortunately, the cell uptake rates of the above peptides in CT26.CL25 cells were poor, with uptake efficiencies of 11.6%, 6.57%, and 24.1%, respectively (Fig. 2a).




Fig. 1 Cationic peptides for mRNA delivery. (a) Protamine/mRNA complex used in clinical trials in treating different cancers. (b) Both H3K4b and H3K(+H)4b are 4-branched peptides, whereas, H3K(+H)4b has an extra histidine at each branch. This alteration results in H3K(+H)4b exhibiting a stronger affinity for mRNA, which subsequently facilitates cell membrane penetration and endosome accumulation.





Fig. 2 Representative amphipathic peptides for mRNA delivery. (a) Representative histograms and a quantified graph of FITC-positive CL26.CL25 cells were obtained by flow cytometry, following transfection with CPP/Fluorescein-labelled mCherry mRNA complexes. Reproduced from ref. 63 with permission from MDPI, copyright 2022. (b) Representative histograms and graphs of EGFP-positive in CT26. CL25 by flow cytometry, following transfection with CPP/GFP mRNA complexes. Reproduced from ref. 63 with permission from MDPI, copyright 2022. (c) The sequence and secondary structure of RALA. Arginine residues are shown in blue, and leucine and alanine residues are shown in red. Reproduced from ref. 44 with permission from John Wiley and Sons, copyright 2017. (d) HELP-4H/mRNA transfection into HCT116 cells. For 1 μg mRNA give the indicated amount of HELP-4H peptide. Reproduced from ref. 47 with permission from John Wiley and Sons, copyright 2021.

Furthermore, based on these delivery systems, no reporter genes were detected at the protein level (Fig. 2b). This might be due to the neutralization of the positive charge on the shorter cationic peptide, which in turn inhibits the complex's ability for internalization as well as affecting the ultimate mRNA delivery efficiency.⁶⁴ Therefore, Mixson's team designed cationic peptides with branching structures to increase the spatial distribution of peptide carriers. It was found that H3K(+H)4b is 10 times more efficient than H3K4b in transfecting luciferase mRNA into MDA-MB-231 cells.⁴² As shown in Fig. 1b, the difference between the two is that H3K4b has four repeat motifs –HHHK– in each branch, while H3K(+H)4b has a similar repeat pattern but with an extra histidine in the second –HHHK–motif of its branches. The reason for the transfection difference is that H3K(+H)4b forms a more stable complex with mRNA compared to H3K4b. This promotes cellular uptake and endosomal accumulation of complexes. This finding indicates that spatial complexity can achieve efficient mRNA delivery of cationic peptides. However, molecules with complex chemical structures that have such multiple repeats usually face greater difficulty and higher costs in synthesis. A simpler and more efficient delivery system still needs to be developed.

2.1.2. Amphipathic peptide-driven mRNA delivery. Cationic peptides bind to nucleic acids *via* electrostatic interactions, but the purely cationic properties may not be sufficient for

transmembrane and intracellular release of nucleic acid drugs. Therefore, researchers have attempted to improve the transmembrane efficiency and endosomal escape ability of peptide carriers, and have developed a series of amphipathic peptides.⁶⁵ Amphipathic peptides contain polar regions of cationic amino acids and non-polar regions of hydrophobic amino acids (such as alanine, valine, leucine, and isoleucine) or hydrophobic groups. The polar region interacts with the phosphate backbone of nucleic acids through electrostatic interactions to achieve nucleic acid encapsulation. The cationic groups are partially exposed on the surface of the nanoparticles to enhance the cellular internalization of the nanoparticles. The non-polar region could effectively promote the interaction between nanoparticles and cell membranes or endosomal membranes by facilitating membrane perturbation. In a word, the amphipathic design can improve the transmembrane ability and enhance the endosomal escape efficiency, thereby achieving the release of nucleic acid drugs in the cytoplasm. Kim *et al.* demonstrated that the amphipathic peptide stearylated Arg8 exhibited enhanced cellular uptake and mRNA transfection compared to the original cationic peptide Arg8 (Fig. 2a and b).⁶³ In addition, the amphipathic peptide p5RHH (VLTTGLPALIS-WIRRRHRRHC) had an outstanding performance, which resulted in a cellular uptake rate of 86.7% and a transfection rate of 86.5% in CT26.CL25 cells, respectively (Fig. 2a and b). Additionally, p5RHH is being commercially developed by Altamira Therapeutics as an mRNA delivery platform. The platform has demonstrated considerable potential in the treatment of osteoarthritis, atherosclerosis, aortic aneurysm, and oncology.^{43,66–68} Presently, other amphipathic peptides including RALA, LAH4-like, HELP-like, and PepFect-like peptides have also been developed for mRNA delivery.

RALA (WEARLARALARALARHLARALARALRACEA) is a 30-amino acid amphipathic cationic α -helical peptide derived from the pH-sensitive peptide GALA and KALA.⁶⁹ The α -helix structure enables the sequence's seven positively charged arginine residues to be gathered on one side, interacting with nucleic acids. The other side of the helix shows an arrangement of hydrophobic leucine residues (Fig. 2c). This structural feature endows RALA with robust and efficient cell-penetrating ability and membrane fusion properties. Moreover, RALA displays a higher capacity for selective membrane disruption under acidic conditions, which significantly facilitates the lysosomal escape of mRNA. One study has shown that mRNA encoding the antigen ovalbumin delivered by RALA could induce a significant ovalbumin-specific T-cell response *in vivo*.⁴⁴ The efficacy of RALA was superior to that of a standard liposomal delivery system prepared with the cationic lipid DOTAP and the fusion lipid DOPE. Also, RALA could safely and effectively deliver CRISPR cargo to primary stem cells for gene editing, providing a delivery method for the application of regenerative medicine and stem cell treatment of genetic diseases.⁷⁰

Histidine-rich peptides are often considered to accelerate the endosomal escape process through the proton sponge phenomenon or “flip-flop” effect. To further improve the lysosomal escape capability of the RALA carrier, Liu *et al.* constructed different vehicles by modulating the ratio of



histidine to arginine.⁷¹ This strategy was verified in plasmid DNA transfection. Compared with the original peptide, HALA2 (WEARLARALARARHLARALAHALHACEA), obtained by replacing the two arginines near the C-terminus with histidine, demonstrated enhanced endosome escape ability and transfection efficiency, but not HALA3/4, which contained 4 histidines. Meanwhile, the comparison between RALA and LAH4-L1, another peptide containing four histidines (KKALLAHALHLLAL-LALHLAHALKKA), revealed superior dendritic cell transfection capabilities of LAH4-L1.⁴⁵ Moreover, replacing the four lysine residues at the ends of LAH4-L1 with arginine residues (named LAH4-L1R) (RRALLAHALHLLALLALHLAHALRRA) also achieved a similar effect. It was confirmed by D'haese *et al.* that both LAH4-L1 and LAH4-L1R can deliver antigen-encoding mRNA and activate antigen-specific T cells.⁴⁶ In addition, both carriers demonstrated self-adjuvant activity for vaccines by inducing the maturation of CD103⁺ DCs and activating inflammasomes.

HELP-4H is another amphipathic α -helix peptide, with a similar design concept to the RALA delivery carrier. By replacing glutamic acid residues with histidine residues, the HELP peptide was transformed to HELP-4H (GLGTLTLLHFLHLLHLLHFLK-RKRQ). The ability of HELP-4H to effectively increase luciferase expression levels in HCT116 tumor cells was confirmed by Ali *et al.* (Fig. 2d).⁴⁷

Meanwhile, different from the above-mentioned amphipathic delivery vehicles composed of complete amino acid sequences, PepFect endows peptide carriers with amphipathic properties by incorporating hydrophobic groups at the terminals of the peptides. For example, PepFect14 (PF14), obtained by replacing the lysine in stearylated TP10 with ornithine, showed stronger resistance to serum proteases. The efficacy of PF14 in delivering diverse nucleic acid therapeutics, including plasmid DNA, siRNA, microRNA (miRNA), and ASO, has been substantiated in multiple studies.^{72–75} In a mouse model of ovarian cancer, PF14 demonstrated superior mRNA transfection and high protein levels in tumor-associated tissues relative to the commercial Lipofectamine MessengerMAX reagent.⁴⁸ Furthermore, PF14-mRNA nanoparticles did not cause immune side effects at the injection site in the irritant contact dermatitis (ICD) mouse model.⁷⁶ Given its favorable biocompatibility, PF14-based mRNA delivery vectors have also been employed in regenerative medicine by introducing them onto porous collagen scaffolds.⁷⁷

2.1.3. Covalently coupled delivery of mRNA and peptides.

The covalent conjugation of nucleic acid drugs and peptides is a common occurrence in small nucleic acids. Recently, some researchers have also introduced the peptide covalent conjugation strategy into the mRNA modification. The Papadopoulos team successfully conjugated the CPP (PFVYLI) to mRNA, where the peptide–puromycin conjugate formed by an amide bond was phosphorylated and then linked to the therapeutic mRNA (Fig. 3).⁴⁹ This covalent conjugation strategy allowed 72% of the mRNA to remain stable after 1 hour of treatment in a high ribonuclease environment. This approach improved the Sco2 protein level in a primary mitochondrial disorders model and increased expression of β -globin in a β -thalassemia model. Nevertheless, the length of mammalian mRNA is typically



Fig. 3 The chemical structure of PFVYLI-mRNA conjugate.

5×10^2 – 1×10^5 nt,⁷⁸ which is considerably longer than that of small nucleic acids (approximately 20 nt). Therefore, how to ensure the stability of mRNA while improving the specificity and yield of covalent conjugation remains a key challenge in the preparation of mRNA peptide conjugates. This also leads to the fact that covalent modification of mRNA with peptides is not the mainstream direction in mRNA delivery.

2.1.4. Phase-separated mediated mRNA delivery. Recently, the concept of phase separation has also been introduced into mRNA delivery. Liquid–liquid phase separation allows a homogeneous mixture to exist in two forms under specific conditions: a low-concentration state in solution and a high-concentration state formed in “droplets”. The two forms can transform into each other in response to alterations in conditions, showing highly dynamic changes.⁷⁹ Studies demonstrated that many macromolecules (including small peptides, enzymes up to 430 kDa, and mRNA) can be rapidly recruited into condensed droplets.^{80,81} Taking advantage of the dynamic properties of phase separation, Ali Miserez’s team developed a peptide condensate HBpep-SR, which can enable efficient mRNA delivery by inducing the aggregation and subsequent disassembly of microdroplets in response to pH and intracellular redox environments (Fig. 4).⁵⁰ The five histidine residues of the peptide endow the system with a pH-responsive liquid–liquid phase separation behavior. In a neutral pH environment, the peptide undergoes rapid phase separation into aggregated droplets, during which it could adsorb and aggregate with various macromolecules from the solution. In an intracellular environment with a low pH and a high concentration of reduced glutathione, the breakage of the reducible disulfide bond exposes the lysine side chain, which accelerates the disintegration of the droplets. The results confirmed that HBpep-SR had a higher mRNA transfection effect than PEI and Lipofectamine 3000 in HepG2 cells, and was as efficient as lipofectamine 2000 in the HEK293 cells. Furthermore, this carrier could be employed for effective gene editing in cells.⁸² The above research illustrated that the introduction of the phase separation concept can effectively protect mRNA from degradation by nucleases while achieving conditionally driven targeted release of mRNA. It is noteworthy that the diameter of the condensed droplets is about 1 μ m, which is contradictory with the traditional concept that






Fig. 4 Phase-separated peptide carriers release mRNA in response to redox conditions.

nanoparticles are more conducive to cellular uptake. This intracellular delivery platform is expected to serve as a promising strategy for macromolecule drug delivery in the treatment of cancer, metabolic diseases, and infectious diseases.

2.2. Hybrid delivery systems involving peptides

Peptides exhibit excellent cell membrane penetration, endosome escape, nuclear targeting, and high target affinity. Thus, peptides can not only be utilized as stand-alone carriers for drug delivery but can also be combined with other carriers to further enhance delivery performance.^{83,84} For instance, studies have found the incorporation of CPPs into liposomes can significantly improve the mRNA transfection capacity. Specifically, the α -helix cationic peptide KALA was modified on liposomes to construct a novel type of anti-tumor vaccine by Tateshita *et al.*⁵¹ On the one hand, the introduction of peptides can aid in the cellular uptake efficiency of liposomes. On the other hand, peptides can be used as vaccine adjuvants to enhance the efficacy of mRNA tumor immunotherapy. Similarly, a novel cationic peptide DP7 (VQWRIRVAVIRK) with antimicrobial activity and vaccine adjuvant properties was presented by Zhang *et al.*⁸⁵ Unfortunately, the introduction of cholesterol modification alone on DP7 did not improve its delivery of mRNA. In 2020, cholesterol-modified DP7 was bound to a liposomal delivery system, successfully achieving personalized mRNA delivery to dendritic cells (Fig. 5a).⁵² The study also confirmed that the introduction of the peptide played an important role in promoting dendritic cell maturation, improving antigen presentation, and increasing the level of pro-inflammatory factor secretion at the cellular level. It also induced an enhanced antigen-specific lymphocyte response and growth inhibition of LL2 tumors in the animal model.




Fig. 5 (a) Cholesterol-modified DP7 was incorporated into a liposomal delivery system, enabling mRNA efficient delivery to dendritic cells and stimulating DC maturation. Reproduced from ref. 52 with permission from Elsevier, copyright 2020. (b) The PEG₁₂KL4 peptide enables efficient mRNA expression in the lungs. Reproduced from ref. 53 with permission from Elsevier, copyright 2019. (c) Schematic diagram of the LAH4-L1/mRNA/PLA complex preparation process.

In addition, the combination of peptides with polymers such as polyethylene glycol and polylactic acid has also demonstrated good clinical application potential for the passive targeting delivery of mRNA. This is especially true for local organ delivery, such as to the lungs. Inhalable mRNA drugs have great potential for treating lung diseases and developing vaccines related to respiratory diseases. However, naked mRNA or complexes based on simple lipid carriers have difficulty penetrating the mucus and surfactant barrier of the lungs to reach epithelial cells deep in the lungs, resulting in poor transfection.^{86,87} In 2017, Qiu *et al.* demonstrated that the hydrophobic peptide KL4, which is a surfactant protein B (SP-B) mimic with a 21-residue cationic peptide containing repeating KLLL sequences, could be employed as a siRNA drug carrier for pulmonary delivery.⁸⁸ Subsequently, the research group modified KL4 with PEG₁₂ to enhance the solubility of the peptide carrier and successfully achieved local expression of luciferase mRNA in the lungs (Fig. 5b).⁵³ Additionally, PEG₁₂ was also introduced by Xu *et al.* onto the amphipathic LAH4-L1 which had markedly improved the mRNA delivery effect of LAH4-L1 in the lung.⁵⁴ Also, some researchers have focused on cell lines that are generally challenging for transfection, such as DC cells and stem cells. Poly(lactic



acid) (PLA) is a biodegradable, negatively charged polymer that has been approved by the FDA for its good biocompatibility. PLA nanoparticles (PLA-NP) can be effectively taken up by dendritic cells *in vivo* and *in vitro*.^{89,90} However, it is difficult for mRNA to be adsorbed onto the PLA-NP surface due to the same negative charge. To solve this problem, PLA-NP mRNA vaccines were prepared by Coolen *et al.* via mixing LAH4-L1 with PLA.⁴⁵ During the preparation process, the mRNA was initially mixed with the amphipathic cationic CPP LAH4-L1 to form a positively charged intermediate complex. Then the intermediate was adsorbed onto the PLA-NPs by electrostatic interaction (Fig. 5c). The PLA-NP/LAH4-L1/mRNA nanocomplexes were unable to transfect into the epithelial cell lines 293T and HeLa but were efficiently taken up by DC2.4 and showed an enhanced transfection effect compared with the LAH4-L1/mRNA complex. The three-component complex was highly taken up by DC cells, which triggered an innate immune response by activating cytoplasmic pattern recognition receptors (PRRs). Besides, it induced an adaptive immune response with a TH1 bias through antigen activation induced by mRNA expression.

Achieving targeted delivery to specific tissues and cells is critical for the clinical translation of mRNA gene therapy. The above-mentioned passive targeting relies on the intrinsic properties of the nanomaterials and the administration routes.⁹¹ While active targeting promotes the specific binding of nanoparticles to corresponding cells through modification of the targeting ligands, thereby improving the efficiency and accuracy of delivery.⁹² Peptides that target cell surface receptors are widely employed to modify lipid- and polymer-based delivery systems, enabling the active targeting delivery of small-molecule drugs and nucleic acids to specific cells and tissues.^{93,94} The molecular weight of peptides is intermediate between that of small molecule drugs and that of antibodies. Hence, peptides possess both the efficient cell membrane penetration ability of small-molecule drugs and the high target affinity of antibodies. In addition, compared to antibodies, peptides offer abundant chemical modification sites and enhanced stability, facilitating their functionalization across various types of delivery systems. In recent years, researchers have combined targeting peptides with other biomaterials to construct nanocomplexes for mRNA delivery. These efforts have advanced mRNA's applications in gene editing, cancer immunotherapy, and neurological disease treatment. For example, it has been shown that RGD peptide-based lipids can be incorporated into LNPs and used to co-deliver Cas9 mRNA and sgRNA, achieving up to 90% GFP knockdown in HepG2 cells with improved efficiency compared with unmodified LNPs.⁹⁵ Also, nanomaterials modified with the anti-PD-L1 peptide DPPA, in combination with ultrasound-targeted microbubble disruption, can be used to deliver IL-15 mRNA to tumors, thereby enhancing tumor immunotherapy.⁹⁶ In addition to tumor targeting, peptides have shown potential in the treatment of other diseases. For instance, studies have shown that PR-targeting peptides can be used to deliver mRNA LNP to retinal neurons, providing a new strategy for the treatment of ocular diseases.⁹⁷ Moreover, the RVG29-targeted peptide can deliver LNP to brain endothelial and

neuronal cells, allowing the mRNA to precisely reach the brain after systemic administration, which is promising for the treatment of neurological diseases.⁹⁸

Peptides contribute significantly to improving the stability, cellular penetration, delivery efficiency, and targeting capability of lipid- or polymer-based mRNA carriers. However, these composite strategies still face challenges related to manufacturing complexity, altered pharmacokinetics, and *in vivo* stability.^{92,99} Nevertheless, these challenges are expected to be positively resolved through further optimization of the peptide and nanoparticle formulations.

3 Internalization mechanism of peptide/mRNA complexes

The mRNA delivered by the carrier needs to go through multiple steps, from adhesion to the cell membrane, cellular uptake *via* direct membrane penetration or endocytosis, escape from endosomes or lysosomes (if endocytosis occurs), to finally release into the cytoplasm followed by mRNA translation. Each of these steps represents a potential barrier to mRNA delivery. Among these steps, cellular uptake is the first barrier for mRNA to exert its function. A comprehensive understanding of the cellular uptake mechanism of mRNA-peptide nanocomplexes is crucial for the rational design of peptide carriers, improving carrier delivery efficiency, and reducing their toxic side effects. Studies showed that peptides enter the cells mainly through energy-independent direct penetration and endocytosis.¹⁰⁰



Fig. 6 Illustration of CPP direct translocation pathways. (a) Inverted micelle formation; (b) pore formation; (c) carpet model; and (d) membrane thinning model.



Early studies suggested that most cell-penetrating peptides enter cells through direct penetration.¹⁰¹ The interaction between the positive charge of CPP and the negatively charged cell membrane components leads to membrane instability and peptide folding on the lipid membrane, therefore allowing CPP to directly penetrate the cell. At present, several hypotheses have been put forth regarding the mechanism of direct permeation, including inverted micelle formation, pore formation, the carpet model, and the membrane thinning model (Fig. 6).¹⁰² Coarse-grained models were employed by Kawamoto *et al.* to investigate the impact of the strong attractive forces between CPPs and lipid head groups on the membrane curvature of a lipid bilayer.¹⁰³ This membrane curvature or indentation could lead to the formation of inverted micelles. It was revealed that the formation of inverted micelles could be a possible mechanism that promotes cell penetration of peptides. The model of transient pore formation is often considered to be the mechanism by which amphipathic peptides are used. For example, the internalization of Pep-1 is carried out by transient pore formation and is dependent on the formation of α -helices.¹⁰⁴ In addition, the carpet model is described as the positively charged segments of the peptide, which are oriented parallel to the membrane surface, bind to the acidic phospholipid head groups, and subsequently form a “carpet”-like covering.¹⁰⁵ When the concentration of the CPP exceeds a threshold, rotation of the peptide leads to the interactions between the hydrophobic residues of the peptide and the hydrophobic core of the membrane, followed by translocation into the cell. The carpet model is often used to describe the mode of action of antimicrobial peptides that retain a positive charge and a hydrophobic structure, such as dermaseptin natural analogs, cecropins, and the human antimicrobial peptide LL-37.¹⁰⁶ An alternative model to the “carpet” model is the “membrane thinning” effect, which was originally proposed for the amphipathic peptide Magainin 2.¹⁰⁷ Specifically, disturbances arise due to the interaction of the negatively charged lipids in the outer membrane with the cationic groups of the CPP. This results in a lateral rearrangement of the lipids and a thinning of the membrane. The accumulation of the CPP on the membrane surface leads to a local reduction in surface tension, which promotes the cellular penetration of the peptides.

In addition to direct penetration-mediated internalization, more studies have discovered that peptides primarily facilitate the cellular entry of mRNA *via* endocytosis (Fig. 7). Pathways of endocytosis include common phagocytosis, macropinocytosis, endocytosis dependent on coat proteins such as clathrin or caveolin, and endocytosis independent of clathrin and/or caveolin. For instance, the peptide sequence PFVYLI can form a covalent complex with Soc2 mRNA and assist Soc2 mRNA entry into fibroblasts by clathrin-dependent endocytosis.⁴⁹ Moreover, the amphipathic peptide delivery system LAH4-L1 was observed to transport mRNA into dendritic cells *via* phagocytosis and clathrin-dependent endocytosis, therefore inducing a powerful and efficient innate immune response.⁴⁵ Shebanova *et al.*¹⁰⁸ used scanning electron microscopy and transmission electron microscopy to study HBpep-SP peptide coacervates. Their findings concluded that HeLa and HepG2 cells took up these coacervates through phagocytosis and




Fig. 7 Reported internalization mechanisms of mRNA peptide carriers. It appears that, at present, the peptide-mediated mRNA cell uptake mechanism is mainly thought to be endocytosis, which encompasses phagocytosis, macropinocytosis, and clathrin-mediated endocytosis.

macropinocytosis. Furthermore, some studies have pointed out that the mechanism of cellular uptake can be closely related to the cell type.⁷⁶ For example, PF14-mRNA nanoparticles were endocytosed *via* macropinocytosis into HeLa cells. When HaCaT cells were used as a model, PF14-mRNA nanoparticles were found to internalize *via* both macropinocytosis and clathrin-mediated endocytosis pathways. Nevertheless, the uptake of PF14-mRNA nanocomplexes by primary keratinocytes was not affected after treatment with different endosomal pathway inhibitors. This indicated that PF14 might internalize into the primary keratinocytes independently of endocytosis. These studies have illustrated that the internalization of mRNA mediated by peptide delivery systems usually cannot be explained by a single pathway, but rather by a simultaneous behavior of multiple pathways. Moreover, other key factors including the sequence composition, chain length of cationic amino acids, hydrophobic properties of the peptide, and the assembly structure of the peptide and mRNA, may also affect the internalization of peptide-based mRNA delivery systems.^{109–113} However, due to the current limited evaluation methods of cell internalization, there is currently no unified understanding of the mechanism of peptide delivery system internalization. It can be foreseen that with the maturity and application of single-cell visualization analysis technology, AI-assisted simulation, and other technologies, we will have a deeper understanding of the mechanism of peptide internalization in the future.

4 Conclusions and outlook

In summary, this review provides a detailed overview of recent research and application prospects of peptide carriers in mRNA drug delivery. Facing stronger negative charges and larger molecular weight, cationic/amphipathic peptide carriers can effectively compress large mRNA molecules to the nanoscale and protect mRNA drugs from ribonuclease degradation. Furthermore, the high cell membrane permeability and lysosome escape ability of



peptide carriers can be utilized to effectively achieve the cytoplasmic delivery of mRNAs and affect the expression of target proteins. In addition to being used alone as a delivery carrier, peptides can also be incorporated with other materials to noticeably improve the cell membrane permeability of traditional delivery carriers while achieving targeted delivery of mRNA to tissues. Moreover, peptide carriers are capable of mRNA drug delivery through non-invasive administration *via* dry powder inhalation, which has demonstrated a strong ability to penetrate mucus and surfactant barriers. This highlights the potential of peptides in inspiring new research directions for the development of therapeutic mRNA drugs and vaccines for lung-related diseases. Moreover, shorter sequences, well-defined structures, and their commercial availability render peptides highly promising candidates for clinical translation.

However, apart from protamine, there have been no other cases of clinical application of peptide-based mRNA carriers. First of all, faced with complex protease systems, peptides still have shortcomings, such as poor stability, easy degradation, and short half-life.¹¹⁴ Optimizing the structure of peptide molecules is expected to circumvent these difficulties. The optimization methods, including replacing the original L-type amino acids with D-type, peptide backbone modifications, and adding protective groups to the N- and C-termini of the molecule, could potentially aid in overcoming these challenges.¹¹⁵ Moreover, various strategies for peptide stapling have been developed to improve the tolerance of peptides to proteases, including ring-closing metathesis between olefinic side chains, lactamization, thiol-ene and thiol-yne, thiol/nitrogen-arylation/alkylation, click-based alkyne cycloaddition, and C-H activation.^{116,117} In addition to this, the introduction of peptide stapling modification strategies enhances the ability of peptide carriers to penetrate cell membranes. For example, stabilized peptides with methionine residues modified with reducible cross-linkers have been applied to improve the druggability of peptide drugs.¹¹⁸ The peptide stapling strategies are expected to become a promising direction in improving the efficacy of peptide-based mRNA delivery carriers.

Secondly, most of the current peptide-mRNA nanoparticles internalize into cells *via* endocytosis, which inevitably faces the problem of poor endosome escape. Recently, by incorporating strategies such as introducing histidines with a proton sponge response and forming pH-sensitive structures, mRNA therapeutics that efficiently achieve endosomal disruption have been successfully developed *in vitro*. Additionally, new transmembrane pathways, such as direct fusion with the cell membrane, are expected to become the design direction for peptide-based mRNA delivery to circumvent the endosome/lysosome metabolic pathway.¹¹⁹

Thirdly, peptide carriers face several potential safety issues.¹²⁰ Leveraging electrostatic interaction to promote the binding and the subsequent membrane penetration of peptides and nucleic acids will unavoidably lead to cation-induced cytotoxicity. Encapsulation of mRNA and intracellular delivery of the complex based on the principle of phase separation is another promising peptide carrier development strategy to overcome this problem.⁵⁰ Finally, how to improve the current problem of ultra-low temperature storage and cold chain

transportation of mRNA with the help of delivery carriers will also be a key focus for the development of new delivery vehicles. It is believed that the introduction of various modification methods and future AI-assisted rational design will provide new directions for the research and development of peptide-based mRNA delivery vehicles.

Author contributions

Conceptualization: Z. L., F. Y.; investigation: H. L., Y. X., K. W.; writing – original draft preparation: H. L., Y. Z.; writing – review and editing: Z. L., F. Y.; funding acquisition: Z. L., F. Y., Y. Z. All authors have read and agreed to the published version of the manuscript.

Data availability

No primary research results, software, or code have been included and no new data were generated or analyzed as part of this review.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Key R&D Program of China (No. 2021YFA0910803), the National Center for Biological Medicine Technology Innovation (NCTIB2022HS01017), the Natural Science Foundation of China grants (22307086), the Natural Science Foundation of Guangdong Province (2022A1515010996), the Shenzhen Science and Technology Program (RCJC20200714114433053, JCYJ20220818095808019), the High-tech Zone Development Special Project of Shenzhen (29853M-KCJ-2023-002-07, GZL202309140842-000049), the Shenzhen High-tech Zone Development Special Plan Pingshan District Innovation Platform Construction Project (29853MKCJ202300208), the Shenzhen Medical Research Fund (D2401004, A2403012), the Tian Fu Jin Cheng Laboratory (Advanced Medical Center) Group Racing Project (TFJC2023010008), and the Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (2019SHIBS0004).

References

- 1 Y. Miao, C. Fu, Z. Yu, L. Yu, Y. Tang and M. Wei, *Acta Pharm. Sin. B*, 2024, **14**, 3802–3817.
- 2 B. Wilson and K. M. Geetha, *J. Drug Delivery Sci. Technol.*, 2022, **74**, 103553.
- 3 Q. Duan, T. Hu, Q. Zhu, X. Jin, F. Chi and X. Chen, *Front. Immunol.*, 2022, **13**, 974433.
- 4 Y. Shi, M. Shi, Y. Wang and J. You, *Signal Transduction Targeted Ther.*, 2024, **9**, 1–43.
- 5 C. Wang and F. Yuan, *Adv. Drug Delivery Rev.*, 2024, **210**, 115340.



- 6 J. S. Turner, J. A. O'Halloran, E. Kalaidina, W. Kim, A. J. Schmitz, J. Q. Zhou, T. Lei, M. Thapa, R. E. Chen, J. B. Case, F. Amanat, A. M. Rausedo, A. Haile, X. Xie, M. K. Klebert, T. Suessen, W. D. Middleton, P.-Y. Shi, F. Krammer, S. A. Teefey, M. S. Diamond, R. M. Presti and A. H. Ellebedy, *Nature*, 2021, **596**, 109–113.
- 7 F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen and W. C. Gruber, *N. Engl. J. Med.*, 2020, **383**, 2603–2615.
- 8 Y. Gu, J. Duan, N. Yang, Y. Yang and X. Zhao, *MedComm*, 2022, **3**, e167.
- 9 C. Krienke, L. Kolb, E. Diken, M. Streuber, S. Kirchhoff, T. Bukur, Ö. Akilli-Öztürk, L. M. Kranz, H. Berger, J. Petschenka, M. Diken, S. Kreiter, N. Yogeve, A. Waisman, K. Karikó, Ö. Türeci and U. Sahin, *Science*, 2021, **371**, 145–153.
- 10 G. Shen, J. Liu, H. Yang, N. Xie and Y. Yang, *J. Controlled Release*, 2024, **369**, 696–721.
- 11 J. Chen, X. Guan, Y. Hu, H. Tian and X. Chen, *Top Curr. Chem.*, 2017, **375**, 32.
- 12 E. Sasso, A. M. D'Alise, N. Zambrano, E. Scarselli, A. Folgori and A. Nicosia, *Semin. Immunol.*, 2020, **50**, 101430.
- 13 Z. Li, Z. Liu, J. Wu and B. Li, *Pharmaceutics*, 2022, **14**, 2699.
- 14 M. Mobasher, R. Ansari, A. M. Castejon, J. Barar and Y. Omid, *Biochim. Biophys. Acta, Gen. Subj.*, 2024, **1868**, 130558.
- 15 P. Boisguérin, K. Konate, E. Josse, E. Vivès and S. Deshayes, *Biomedicines*, 2021, **9**, 583.
- 16 R. D. Kirian, D. Steinman, C. M. Jewell and H. C. Zierden, *Theranostics*, 2024, **14**, 2265.
- 17 M. Zhao, R. Wang, K. Yang, Y. Jiang, Y. Peng, Y. Li, Z. Zhang, J. Ding and S. Shi, *Acta Pharm. Sin. B*, 2023, **13**, 916–941.
- 18 W. Zhang, Y. Liu, J. Min Chin and K. K. L. Phua, *Eur. J. Pharm. Biopharm.*, 2021, **163**, 179–187.
- 19 M. Li, M. Zhao, Y. Fu, Y. Li, T. Gong, Z. Zhang and X. Sun, *J. Controlled Release*, 2016, **228**, 9–19.
- 20 M. Li, Y. Li, K. Peng, Y. Wang, T. Gong, Z. Zhang, Q. He and X. Sun, *Acta Biomater.*, 2017, **64**, 237–248.
- 21 X. Ke, L. Shelton, Y. Hu, Y. Zhu, E. Chow, H. Tang, J. L. Santos and H.-Q. Mao, *ACS Appl. Mater. Interfaces*, 2020, **12**, 35835–35844.
- 22 Z. Iqbal, K. Rehman, A. Mahmood, M. Shabbir, Y. Liang, L. Duan and H. Zeng, *J. Nanobiotechnol.*, 2024, **22**, 395.
- 23 H. Kim, Y. Park and J. B. Lee, *Sci. Rep.*, 2015, **5**, 12737.
- 24 X. Fu, T. Chen, Y. Song, C. Feng, H. Chen, Q. Zhang, G. Chen and X. Zhu, *Small*, 2021, **17**, e2101224.
- 25 N. Yoshinaga, E. Cho, K. Koji, Y. Mochida, M. Naito, K. Osada, K. Kataoka, H. Cabral and S. Uchida, *Angew. Chem., Int. Ed.*, 2019, **58**, 11360–11363.
- 26 I. Urits, D. Swanson, M. C. Swett, A. Patel, K. Bernardino, A. Amgalan, A. A. Berger, H. Kassem, A. D. Kaye and O. Viswanath, *Neurol. Ther.*, 2020, **9**, 301–315.
- 27 R. Tenchov, R. Bird, A. E. Curtze and Q. Zhou, *ACS Nano*, 2021, **15**, 16982–17015.
- 28 S.-H. Bae, S. Yoo, J. Lee, H.-J. Park, S. P. Kwon, H. Jin, S.-I. Park, Y.-S. Lee, Y.-J. Bang, G. Roh, S. Lee, S. B. Youn, I. W. Kim, H. R. Oh, A. K. El-Damasy, G. Keum, H. Kim, H. Youn, J.-H. Nam and E.-K. Bang, *Bioact. Mater.*, 2024, **38**, 486–498.
- 29 X. Wang, S. Liu, Y. Sun, X. Yu, S. M. Lee, Q. Cheng, T. Wei, J. Gong, J. Robinson, D. Zhang, X. Lian, P. Basak and D. J. Siegwart, *Nat. Protoc.*, 2023, **18**, 265–291.
- 30 L. Zheng, S. R. Bandara, Z. Tan and C. Leal, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2301067120.
- 31 E. Oude Blenke, E. Örnsov, C. Schöneich, G. A. Nilsson, D. B. Volkin, E. Mastrobattista, Ö. Almarsson and D. J. A. Crommelin, *J. Pharm. Sci.*, 2023, **112**, 386–403.
- 32 A.-G. Reinhart, A. Osterwald, P. Ringler, Y. Leiser, M. E. Lauer, R. E. Martin, C. Ullmer, F. Schumacher, C. Korn and M. Keller, *Mol. Pharmaceutics*, 2023, **20**, 6492–6503.
- 33 S. Al-Halifa, M. Babych, X. Zottig, D. Archambault and S. Bourgault, *Pept. Sci.*, 2019, **111**, e24095.
- 34 C. J. C. Edwards-Gayle and I. W. Hamley, *Org. Biomol. Chem.*, 2017, **15**, 5867–5876.
- 35 L. B. De Martini, C. Sulmona, L. Brambilla and D. Rossi, *Cells*, 2023, **12**, 1643.
- 36 S. H. Nam, J. Park and H. Koo, *Arch. Pharm. Res.*, 2023, **46**, 18–34.
- 37 N. Naowarajna, R. Cheng, J. Lopez, C. Wong, L. Qiao and P. Liu, *Synth. Syst. Biotechnol.*, 2021, **6**, 32–49.
- 38 W. Liang, P. C. L. Kwok, M. Y. T. Chow, P. Tang, A. J. Mason, H.-K. Chan and J. K. W. Lam, *Eur. J. Pharm. Biopharm.*, 2014, **86**, 64–73.
- 39 M. Y. T. Chow and J. K. W. Lam, *Curr. Pharm. Des.*, 2015, **21**, 3854–3866.
- 40 *StatPearls*, <https://www.ncbi.nlm.nih.gov/books/NBK562260/> (accessed November 2024).
- 41 M. Alberer, U. Gnad-Vogt, H. S. Hong, K. T. Mehr, L. Backert, G. Finak, R. Gottardo, M. A. Bica, A. Garofano, S. D. Koch, M. Fotin-Mleczek, I. Hoerr, R. Clemens and F. von Sonnenburg, *The Lancet*, 2017, **390**, 1511–1520.
- 42 J. He, S. Xu, Q. Leng and A. J. Mixson, *J. Gene Med.*, 2021, **23**, e3295.
- 43 J. H. Lockhart, J. VanWye, R. Banerjee, S. A. Wickline, H. Pan and H. Totary-Jain, *Mol. Ther.*, 2021, **29**, 1744–1757.
- 44 V. K. Udhayakumar, A. De Beuckelaer, J. McCaffrey, C. M. McCrudden, J. L. Kirschman, D. Vanover, L. Van Hoecke, K. Roose, K. Deswarte, B. G. De Geest, S. Lienenklaus, P. J. Santangelo, J. Grooten, H. O. McCarthy and S. De Koker, *Adv. Healthcare Mater.*, 2017, **6**, 1601412.
- 45 A.-L. Coolen, C. Lacroix, P. Mercier-Gouy, E. Delaune, C. Monge, J.-Y. Exposito and B. Verrier, *Biomaterials*, 2019, **195**, 23–37.
- 46 S. D'haese, S. Laeremans, S. den Roover, S. D. Allard, G. Vanham and J. L. Aerts, *Pharmaceutics*, 2022, **14**, 1387.



- 47 S. Ali, C. Dussouillez, B. Padilla, B. Frisch, A. J. Mason and A. Kichler, *J. Gene Med.*, 2022, **24**, e3401.
- 48 D. van den Brand, M. A. J. Gorris, A. H. van Asbeck, E. Palmen, I. Ebisch, H. Dolstra, M. Hällbrink, L. F. A. G. Massuger and R. Brock, *Eur. J. Pharm. Biopharm.*, 2019, **141**, 180–190.
- 49 A. N. Miliotou, I. S. Pappas, G. Spyroulias, E. Vlachaki, A. S. Tsiftoglou, I. S. Vizirianakis and L. C. Papadopoulou, *Mol. Ther. – Nucleic Acids*, 2021, **26**, 694–710.
- 50 Y. Sun, S. Y. Lau, Z. W. Lim, S. C. Chang, F. Ghadessy, A. Partridge and A. Miserez, *Nat. Chem.*, 2022, **14**, 274–283.
- 51 N. Tateshita, N. Miura, H. Tanaka, T. Masuda, S. Ohtsuki, K. Tange, Y. Nakai, H. Yoshioka and H. Akita, *J. Controlled Release*, 2019, **310**, 36–46.
- 52 R. Zhang, L. Tang, Y. Tian, X. Ji, Q. Hu, B. Zhou, Z. Ding, H. Xu and L. Yang, *J. Controlled Release*, 2020, **328**, 210–221.
- 53 Y. Qiu, R. C. H. Man, Q. Liao, K. L. K. Kung, M. Y. T. Chow and J. K. W. Lam, *J. Controlled Release*, 2019, **314**, 102–115.
- 54 Y. Xu, Y. Zheng, X. Ding, C. Wang, B. Hua, S. Hong, X. Huang, J. Lin, P. Zhang and W. Chen, *Drug Delivery*, 2023, **30**, 2219870.
- 55 Y. Gu, J. Chen, Z. Wang, C. Liu, T. Wang, C.-J. Kim, H. Durikova, S. Fernandes, D. N. Johnson, R. De Rose, C. Cortez-Jugo and F. Caruso, *Nat. Commun.*, 2024, **15**, 9664.
- 56 Y.-S. Wang, M. Kumari, G.-H. Chen, M.-H. Hong, J. P.-Y. Yuan, J.-L. Tsai and H.-C. Wu, *J. Biomed. Sci.*, 2023, **30**, 84.
- 57 F. Veider, E. Sanchez Armengol and A. Bernkop-Schnürch, *Small*, 2024, **20**, 2304713.
- 58 H. Amos, *Biochem. Biophys. Res. Commun.*, 1961, **5**, 1–4.
- 59 N. T. Jarzebska, M. Mellett, J. Frei, T. M. Kündig and S. Pascolo, *Pharmaceutics*, 2021, **13**, 877.
- 60 F. Friedberg, T. Winnick and D. M. Greenberg, *J. Biol. Chem.*, 1947, **169**, 763.
- 61 J. Liu, S. Guo, Z. Li, L. Liu and J. Gu, *Colloids Surf., B*, 2009, **73**, 36–41.
- 62 L. Falato, M. Gestin and Ü. Langel, *Design and Delivery of siRNA Therapeutic*, Humana, New York, 2021.
- 63 Y. Kim, H. Kim, E. H. Kim, H. Jang, Y. Jang, S.-G. Chi, Y. Yang and S. H. Kim, *Pharmaceutics*, 2022, **14**, 1271.
- 64 R. H. Mo, J. L. Zaro and W.-C. Shen, *Mol. Pharmaceutics*, 2012, **9**, 299–309.
- 65 L. Luan, Q. Meng, L. Xu, Z. Meng, H. Yan and K. Liu, *J. Mater. Chem. B*, 2015, **3**, 1068–1078.
- 66 H. Yan, Y. Hu, A. Akk, M. F. Rai, H. Pan, S. A. Wickline and C. T. N. Pham, *Pharmaceutics*, 2020, **12**, 73.
- 67 H. Yan, Y. Hu, Y. Lyu, A. Akk, A. C. Hirbe, S. A. Wickline, H. Pan, E. D. O. Roberson and C. T. N. Pham, *bioRxiv*, 2024, preprint, DOI: [10.1101/2024.06.17.599454](https://doi.org/10.1101/2024.06.17.599454).
- 68 A. U. Kabir, C. Zeng, M. Subramanian, J. Wu, M. Kim, K. Krehma, X. Wang, C. M. Halabi, H. Pan, S. A. Wickline, D. H. Fremont, M. N. Artyomov and K. Choi, *Nat. Immunol.*, 2024, **25**, 1546–1554.
- 69 H. O. McCarthy, J. McCaffrey, C. M. McCrudden, A. Zholobenko, A. A. Ali, J. W. McBride, A. S. Massey, S. Pentlavalli, K.-H. Chen, G. Cole, S. P. Loughran, N. J. Dunne, R. F. Donnelly, V. L. Kett and T. Robson, *J. Controlled Release*, 2014, **189**, 141–149.
- 70 J. P. Graham, J. G. Castro, L. C. Werba, L. C. Fardone, K. P. Francis, A. Ramamurthi, M. Layden, H. O. McCarthy and T. Gonzalez-Fernandez, *bioRxiv*, 2024, preprint, DOI: [10.1101/2024.09.23.614499](https://doi.org/10.1101/2024.09.23.614499).
- 71 Y. Liu, H.-H. Wan, D.-M. Tian, X.-J. Xu, C.-L. Bi, X.-Y. Zhan, B.-H. Huang, Y.-S. Xu and L.-P. Yan, *Materials*, 2021, **14**, 4674.
- 72 K.-L. Veiman, I. Mäger, K. Ezzat, H. Margus, T. Lehto, K. Langel, K. Kurrikoff, P. Arukuusk, J. Suhorutšenko, K. Padari, M. Pooga, T. Lehto and Ü. Langel, *Mol. Pharmaceutics*, 2013, **10**, 199–210.
- 73 E.-H. Ervin, M. Pook, I. Teino, V. Kasuk, A. Trei, M. Pooga and T. Maimets, *Stem Cell Res. Ther.*, 2019, **10**, 43.
- 74 G. Carreras-Badosa, J. Maslovskaja, K. Periyasamy, E. Urgard, K. Padari, H. Vaher, L. Tserel, M. Gestin, K. Kisand, P. Arukuusk, C. Lou, Ü. Langel, J. Wengel, M. Pooga and A. Rebane, *Biomaterials*, 2020, **262**, 120316.
- 75 C. Pasquale Cerrato, T. Kivijärvi, R. Tozzi, T. Lehto, M. Gestin and Ü. Langel, *J. Mater. Chem. B*, 2020, **8**, 10825–10836.
- 76 K. Periyasamy, M. Maloverjan, A. Biswas, A. Remm, M. Pook, A. Rebane and M. Pooga, *Front. Pharmacol.*, 2023, **14**, 1219761.
- 77 R. Oude Egberink, H. M. Zegelaar, N. El Boujnouni, E. M. M. Versteeg, W. F. Daamen and R. Brock, *Pharmaceutics*, 2022, **14**, 1619.
- 78 S. S. Sommer and J. E. Cohen, *J. Mol. Evol.*, 1980, **15**, 37–57.
- 79 F. Späth, C. Donau, A. M. Bergmann, M. Kränzlein, C. V. Synatschke, B. Rieger and J. Boekhoven, *J. Am. Chem. Soc.*, 2021, **143**, 4782–4789.
- 80 Z. W. Lim, Y. Ping and A. Miserez, *Bioconjugate Chem.*, 2018, **29**, 2176–2180.
- 81 Z. W. Lim, V. B. Varma, R. V. Ramanujan and A. Miserez, *Acta Biomater.*, 2020, **110**, 221–230.
- 82 Y. Sun, X. Xu, L. Chen, W. L. Chew, Y. Ping and A. Miserez, *ACS Nano*, 2023, **17**, 16597–16606.
- 83 M. Liu, X. Fang, Y. Yang and C. Wang, *Front. Bioeng. Biotechnol.*, 2021, **9**, 701504.
- 84 Y. Wang, L. Zhang, C. Liu, Y. Luo and D. Chen, *Pharmaceutics*, 2024, **16**, 240.
- 85 R. Zhang, L. Tang, Y. Tian, X. Ji, Q. Hu, B. Zhou, D. Zhenyu, X. Heng and L. Yang, *Biomaterials*, 2020, **241**, 119852.
- 86 Q. Wang, C. Bu, Q. Dai, J. Chen, R. Zhang, X. Zheng, H. Ren, X. Xin and X. Li, *Adv. Sci.*, 2024, **11**, e2309748.
- 87 X. M. Bustamante-Marin and L. E. Ostrowski, *Cold Spring Harbor Perspect. Biol.*, 2017, **9**, a028241.
- 88 Y. Qiu, M. Y. T. Chow, W. Liang, W. W. Y. Chung, J. C. W. Mak and J. K. W. Lam, *Mol. Pharmaceutics*, 2017, **14**, 4606–4617.
- 89 C. Primard, N. Rochereau, E. Luciani, C. Genin, T. Delair, S. Paul and B. Verrier, *Biomaterials*, 2010, **31**, 6060–6068.
- 90 J. Rességuier, E. Delaune, A.-L. Coolen, J.-P. Levrard, P. Boudinot, D. Le Guellec and B. Verrier, *Front. Immunol.*, 2017, **8**, 190.



- 91 R. A. Meyer, S. Y. Neshat, J. J. Green, J. L. Santos and A. D. Tuesca, *Mater. Today Adv.*, 2022, **14**, 100240.
- 92 J. Di, P. Huang and X. Chen, *Bioconjugate Chem.*, 2024, **35**, 453–456.
- 93 I. Truebenbach, W. Zhang, Y. Wang, S. Kern, M. Höhn, S. Reinhard, J. Gorges, U. Kazmaier and E. Wagner, *Int. J. Pharm.*, 2019, **569**, 118570.
- 94 B. M. Cooper, J. Iegre, D. H. O. Donovan, M. Ö. Halvarsson and D. R. Spring, *Chem. Soc. Rev.*, 2021, **50**, 1480–1494.
- 95 J. Qin, L. Xue, N. Gong, H. Zhang, S. J. Shepherd, R. M. Haley, K. L. Swingle and M. J. Mitchell, *RSC Adv.*, 2022, **12**, 25397–25404.
- 96 X. Wang, F. Li, J. Zhang, L. Guo, M. Shang, X. Sun, S. Xiao, D. Shi, D. Meng, Y. Zhao, C. Jiang and J. Li, *J. Controlled Release*, 2024, **367**, 45–60.
- 97 M. Herrera-Barrera, R. C. Ryals, M. Gautam, A. Jozic, M. Landry, T. Korzun, M. Gupta, C. Acosta, J. Stoddard, R. Reynaga, W. Tschetter, N. Jacomino, O. Taratula, C. Sun, A. K. Lauer, M. Neuringer and G. Sahay, *Sci. Adv.*, 2023, **9**, eadd4623.
- 98 E. L. Han, S. Tang, D. Kim, A. M. Murray, K. L. Swingle, A. G. Hamilton, K. Mrksich, M. S. Padilla, R. Palanki, J. J. Li and M. J. Mitchell, *Nano Lett.*, 2025, **25**, 800–810.
- 99 I. Menon, M. Zaroudi, Y. Zhang, E. Aisenbrey and L. Hui, *Mater. Today Adv.*, 2022, **16**, 100299.
- 100 I. Ruseska and A. Zimmer, *Beilstein J. Nanotechnol.*, 2020, **11**, 101–123.
- 101 F. Madani, S. Lindberg, U. Langel, S. Futaki and A. Gräslund, *J. Biophys.*, 2011, **2011**, 414729.
- 102 J. Ouyang, Y. Sheng and W. Wang, *Cells*, 2022, **11**, 4016.
- 103 S. Kawamoto, M. Takasu, T. Miyakawa, R. Morikawa, T. Oda, S. Futaki and H. Nagao, *J. Chem. Phys.*, 2011, **134**, 095103.
- 104 S. Deshayes, M. C. Morris, G. Divita and F. Heitz, *Biochim. Biophys. Acta, Biomembr.*, 2006, **1758**, 328–335.
- 105 Y. Pouny, D. Rapaport, A. Mor, P. Nicolas and Y. Shai, *Biochemistry*, 1992, **31**, 12416–12423.
- 106 Y. Shai and Z. Oren, *Peptides*, 2001, **22**, 1629–1641.
- 107 S. Ludtke, K. He and H. Huang, *Biochemistry*, 1995, **34**, 16764–16769.
- 108 A. Shebanova, Q. M. Perrin, K. Zhu, S. Gudlur, Z. Chen, Y. Sun, C. Huang, Z. W. Lim, E. A. Mondarte, R. Sun, S. Lim, J. Yu, Y. Miao, A. N. Parikh, A. Ludwig and A. Miserez, *Adv. Sci.*, 2024, **11**, e2402652.
- 109 K. D. Saint Jean, K. D. Henderson, C. L. Chrom, L. E. Abiuso, L. M. Renn and G. A. Caputo, *Probiotics Antimicrob. Proteins*, 2018, **10**, 408–419.
- 110 J. Allen and J.-P. Pellois, *Sci. Rep.*, 2022, **12**, 15981.
- 111 C. Rudolph, C. Plank, J. Lausier, U. Schillinger, R. H. Müller and J. Rosenecker, *J. Biol. Chem.*, 2003, **278**, 11411–11418.
- 112 E. Hinde, K. Thammasiraphop, H. T. T. Duong, J. Yeow, B. Karagoz, C. Boyer, J. J. Gooding and K. Gaus, *Nat. Nanotechnol.*, 2017, **12**, 81–89.
- 113 D. P. Jana, D. K. Samanta, D. M. Ehlers, E. Zellermann, D. S. Bäcker, P. R. H. Stauber, P. D. C. Schmuck and P. S. K. Knauer, *ChemBioChem*, 2022, **24**, e202200519.
- 114 L. Diao and B. Meibohm, *Clin. Pharmacokinet.*, 2013, **52**, 855–868.
- 115 S. M. Shi and L. Di, in *Peptide Therapeutics: Fundamentals of Design, Development, and Delivery*, ed. S. D. Jois, Springer, Cham, 1, 2022, vol. 4, 163–182.
- 116 D. P. Fairlie and A. Dantas de Araujo, *Pept. Sci.*, 2016, **106**, 843–852.
- 117 M. Moiola, M. G. Memeo and P. Quadrelli, *Molecules*, 2019, **24**, 3654.
- 118 W. Li, D. Wang, X. Shi, J. Li, Y. Ma, Y. Wang, T. Li, J. Zhang, R. Zhao, Z. Yu, F. Yin and Z. Li, *Mater. Horiz.*, 2018, **5**, 745–752.
- 119 D. W. Brown, P. Wee, P. Bhandari, A. Bukhari, L. Grin, H. Vega, M. Hejazi, D. Sosnowski, J. Ablack, E. K. Clancy, D. Pink, J. Kumar, M. P. S. Ares, S. Lamb, R. Quevedo, B. Rawal, F. Elian, N. Rana, L. Morales, N. Govindasamy, B. Todd, A. Delmage, S. Gupta, N. McMullen, D. MacKenzie, P. H. Beatty, H. Garcia, M. Parmar, J. Gyoba, C. McAllister, M. Scholz, R. Duncan, A. Raturi and J. D. Lewis, *Cell*, 2024, **187**, 5357–5375.e24.
- 120 Y. J. Park, J. F. Liang, K. S. Ko, S. W. Kim and V. C. Yang, *J. Gene Med.*, 2003, **5**, 700–711.

